Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Doxorubicin Hydrochloride

FDA-approved product (injectable, injection), marketed as Adriamycin Pfs, Doxil (Liposomal), Doxorubicin Hydrochloride and 2 more.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Doxorubicin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute myelomonocytic leukemia
  • Bone sarcoma
  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Carcinoma
  • Childhood epithelioid sarcoma
  • Classic Hodgkin lymphoma
  • Epithelioid sarcoma
  • Heart failure
  • HER2 Positive Breast Carcinoma
  • Hodgkins lymphoma
  • Kaposi's sarcoma
  • Malignant epithelial tumor of ovary
  • Multiple myeloma
  • and 9 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anthracyclines and related substances
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA6.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 0 of 1 lab record
Open Doxorubicin Hydrochloride in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Doxorubicin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS

    NCT07076186 · start 2025-10-02

    Registered record
    Registry ID
    NCT07076186
    Conditions
    Uterine Leiomyosarcoma
    Interventions
    Trabectedin; Doxorubicin Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-10-02
    Completion
    2029-12-02
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUterine Leiomyosarcoma
    InterventionTrabectedin; Doxorubicin Hydrochloride
    PhasePhase 2
    Registry statusRecruiting

  • Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

    NCT05996185 · start 2024-10-09

    Registered record
    Registry ID
    NCT05996185
    Conditions
    T Cell Lymphoma; T-cell Lymphoma
    Interventions
    Mogamulizumab; DA-EPOCH Protocol; CHOEP protocol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-10-09
    Completion
    2027-11
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionT Cell Lymphoma; T-cell Lymphoma
    InterventionMogamulizumab; DA-EPOCH Protocol; CHOEP protocol
    PhasePhase 2
    Registry statusRecruiting

  • Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage

    NCT05731375 · start 2023-12-28

    Registered record
    Registry ID
    NCT05731375
    Conditions
    Doxorubicin Induced Cardiomyopathy; Chemotherapeutic Toxicity; Anthracyclines
    Interventions
    31-MRS at 7 Tesla (T)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-12-28
    Completion
    2026-03-20
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDoxorubicin Induced Cardiomyopathy; Chemotherapeutic Toxicity; Anthracyclines
    Intervention31-MRS at 7 Tesla (T)
    PhaseNot recorded
    Registry statusCompleted

  • Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

    NCT05820841 · start 2023-06-07

    Registered record
    Registry ID
    NCT05820841
    Conditions
    Large B-cell Lymphoma; Diffuse Large B Cell Lymphoma
    Interventions
    R-miniCHOP + Acalabrutinib; R-miniCHOP
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-06-07
    Completion
    2029-02
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLarge B-cell Lymphoma; Diffuse Large B Cell Lymphoma
    InterventionR-miniCHOP + Acalabrutinib; R-miniCHOP
    PhasePhase 3
    Registry statusRecruiting

  • Ice Plant Intensive Cream for the Prevention of Hand-Foot Syndrome in Breast Cancer: Pilot Randomized Controlled Trial

    NCT05755646 · start 2023-03-10

    Registered record
    Registry ID
    NCT05755646
    Conditions
    Hand-Foot Syndrome; Breast Cancer
    Interventions
    Ice Plant Intensive Cream plus Standard Care; Standard Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-03-10
    Completion
    2024-05-06
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHand-Foot Syndrome; Breast Cancer
    InterventionIce Plant Intensive Cream plus Standard Care; Standard Care
    PhaseNot applicable
    Registry statusCompleted

  • Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

    NCT05595109 · start 2022-10-28

    Registered record
    Registry ID
    NCT05595109
    Conditions
    Breast Cancer; Peripheral Neuropathy; Cardiac Toxicities; Hepatic Toxicity; Cognitive Impairment
    Interventions
    Silymarin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2022-10-28
    Completion
    2024-10-28
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Peripheral Neuropathy; Cardiac Toxicities; Hepatic Toxicity +1 more
    InterventionSilymarin; Placebo
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)

    NCT05913427 · start 2022-06-08

    Registered record
    Registry ID
    NCT05913427
    Conditions
    Adrenocortical Carcinoma
    Interventions
    Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG; Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-06-08
    Completion
    2027-06-08
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdrenocortical Carcinoma
    InterventionEtoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG; Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

    NCT05092360 · start 2022-01-10

    Registered record
    Registry ID
    NCT05092360
    Conditions
    Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
    Interventions
    Nemvaleukin and Pembrolizumab Combination; Pembrolizumab; Nemvaleukin; Pegylated Liposomal Doxorubicin (PLD); Paclitaxel; Topotecan; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2022-01-10
    Completion
    2025-05-08
    Enrolment
    456

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlatinum-resistant Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
    InterventionNemvaleukin and Pembrolizumab Combination; Pembrolizumab; Nemvaleukin; Pegylated Liposomal Doxorubicin (PLD) +3 more
    PhasePhase 3
    Registry statusTerminated

  • The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC

    NCT04877821 · start 2021-09-15

    Registered record
    Registry ID
    NCT04877821
    Conditions
    Triple Negative Breast Cancer
    Interventions
    Sintilimab; Anlotinib; Nab paclitaxel; Carboplatin; Epirubicin; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-09-15
    Completion
    2026-03-10
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Cancer
    InterventionSintilimab; Anlotinib; Nab paclitaxel; Carboplatin +2 more
    PhasePhase 2
    Registry statusCompleted

  • Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)

    NCT04692155 · start 2021-08-31

    Registered record
    Registry ID
    NCT04692155
    Conditions
    Mantle Cell Lymphoma
    Interventions
    Ublituximab; Umbralisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2021-08-31
    Completion
    2022-06-30
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma
    InterventionUblituximab; Umbralisib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

    NCT04908787 · start 2021-06-11

    Registered record
    Registry ID
    NCT04908787
    Conditions
    Ovarian Cancer
    Interventions
    BD0801; Paclitaxel; Placebo; Topotecan; doxorubicin liposome
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-06-11
    Completion
    2024-10-11
    Enrolment
    421

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionBD0801; Paclitaxel; Placebo; Topotecan +1 more
    PhasePhase 3
    Registry statusCompleted

  • The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

    NCT04753177 · start 2021-01-28

    Registered record
    Registry ID
    NCT04753177
    Conditions
    The Neoadjuvant Therapy
    Interventions
    Ribocyclib, fulvestrant, triptorelin; Doxorubicin, cyclophosphamide, paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2021-01-28
    Completion
    2024-01-28
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThe Neoadjuvant Therapy
    InterventionRibocyclib, fulvestrant, triptorelin; Doxorubicin, cyclophosphamide, paclitaxel
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer

    NCT04498793 · start 2020-09

    Registered record
    Registry ID
    NCT04498793
    Conditions
    HER2-negative Breast Cancer
    Interventions
    Tislelizumab; Nab paclitaxel; Doxorubicin; Epirubicin; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-09
    Completion
    2022-12
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-negative Breast Cancer
    InterventionTislelizumab; Nab paclitaxel; Doxorubicin; Epirubicin +1 more
    PhasePhase 2
    Registry statusUnknown

  • A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

    NCT04061772 · start 2019-08-12

    Registered record
    Registry ID
    NCT04061772
    Conditions
    Peripheral T Cell Lymphoma
    Interventions
    Bortezomib; Etoposide; Cyclophosphamide; Pharmorubicin; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-08-12
    Completion
    2021-12-05
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral T Cell Lymphoma
    InterventionBortezomib; Etoposide; Cyclophosphamide; Pharmorubicin +1 more
    PhasePhase 2
    Registry statusUnknown

  • ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

    NCT04172259 · start 2019-01-10

    Registered record
    Registry ID
    NCT04172259
    Conditions
    Breast Cancer; Neoadjuvant Chemotherapy
    Interventions
    Doxorubicin liposome; Cyclophosphamide; Trastuzumab; Docetaxel; Epirubicin; Pertuzumab; Paclitaxel; Paclitaxel-albumin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-01-10
    Completion
    2026-09-30
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Neoadjuvant Chemotherapy
    InterventionDoxorubicin liposome; Cyclophosphamide; Trastuzumab; Docetaxel +4 more
    PhasePhase 2
    Registry statusActive not recruiting